Aptamer library
Info Center
  • Cancer Cell Aptamer Screening Service

    Core Concept: Aptamers vs. Antibodies Aptamers are often called "chemical antibodies." Their key advantages for cancer targeting include: Small size: Better tissue penetration. In vitro synthesis: Highly reproducible, no batch-to-batch variation. Ease of modification: Can be chemically tagged with dyes, drugs, or nanoparticles. Low immunogenicity. Target Range: Can bind to proteins, carbohydrates, lipids, or even complex molecular patterns on a whole cell's surface. The Screening Service Workflow (Cell-SELEX) A typical service follows these steps: 1. Project Design & Target Selection Client Input: You define the target (e.g., "Aptamers for metastatic triple-negative breast cancer cell line MDA-MB-231"). Counter-Selection: Crucial step. To ensure specificity, the service provider will also use a control cell line (e.g., normal breast epithelial cells or a less aggressive cancer type) to remove aptamers that bind to common, non-target molecules. Library Design: The provider uses a vast random oligonucleotide library (e.g., 10^14 different sequences). 2. The SELEX Process This is an iterative, multi-round biochemical "fishing" experiment: Incubation: The library is exposed to the target cancer cells. Washing: Weakly or unbound sequences are washed away. Elution: Bound aptamers are recovered (e.g., by heating or trypsinizing cells). Amplification: Recovered aptamers are amplified by PCR (for DNA) or RT-PCR (for RNA). Stringency Increase: In each subsequent round, conditions become stricter (more washing, shorter incubation, addition…

    2026-01-15
  • Viral Capsid Protein Aptamer Screening Service

    What is the Core Service? The service provider uses an iterative, in vitro selection process called SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to screen vast random oligonucleotide libraries (10^14 - 10^15 unique sequences) against your target protein. The output is a set of characterized aptamer sequences that bind to the viral capsid. Standardized Screening Workflow A professional service will manage this entire pipeline: 1. Project Design & Target Preparation: Target Discussion: Defining the specific capsid protein (e.g., HIV-1 CA, HBV core, SARS-CoV-2 N), its form (full-length, domain, assembled capsid/nucleocapsid), and purity. Target Immobilization: The protein is often immobilized on a solid support (beads, plate) to facilitate separation of bound/unbound sequences. Some services offer solution-phase or capillary electrophoresis (CE-SELEX) methods for higher stringency. 2. SELEX Selection Rounds (Cycles 5-15): Incubation: The oligonucleotide library is incubated with the target. Partitioning: Unbound sequences are washed away; bound sequences are retained. Elution: Bound aptamers are eluted (e.g., by heating, denaturing agents). Amplification: Eluted aptamers are amplified by PCR (for DNA) or RT-PCR (for RNA). Purification: The amplified pool is purified for the next selection round. Counter-Selection: To ensure specificity, the pool is often passed through a negative control (e.g., irrelevant protein, cell lysate) to remove non-specific binders. 3. Sequencing & Identification: High-Throughput…

    2026-01-14
  • Antibody Aptamer Screening Service

    What is an Antibody Aptamer Screening Service? It is a specialized contract research service where a biotechnology company uses SELEX (Systematic Evolution of Ligands by EXponential Enrichment) or advanced variations of it to discover and develop aptamers that bind with high affinity and specificity to a target antibody. Antibody: A large, Y-shaped protein produced by the immune system to identify and neutralize pathogens. Aptamer: A short, single-stranded DNA or RNA oligonucleotide (or a modified derivative) that folds into a specific 3D structure, enabling it to bind to a target molecule with antibody-like specificity. Often called "chemical antibodies." The goal of the service is to provide clients with synthetic, recombinant-like binding molecules as alternatives or complements to traditional monoclonal antibodies. Why Screen for Aptamers Against Antibodies? Aptamers offer distinct advantages, making them attractive for various applications: Anti-Drug Antibody (ADA) Detection: Develop aptamer-based assays to detect and quantify ADAs in clinical trials for biotherapeutics. Diagnostic Tools: Create aptamer sensors (aptasensors) to detect specific antibody biomarkers for diseases (e.g., autoantibodies in autoimmune disorders). Therapeutic Neutralization: Discover aptamers that can bind and neutralize pathological antibodies (e.g., in autoimmune diseases like lupus or myasthenia gravis). Purification & Pull-Down: Use aptamers as ligands in chromatography or in assays to capture and isolate specific antibodies from complex…

    2026-01-14
  • Metal Ion-Targeted Aptamer Screening Service

    What is a Metal Ion-Targeted Aptamer Screening Service? It is a contract research service where a specialized laboratory uses an in vitro selection process (most commonly SELEX - Systematic Evolution of Ligands by EXponential Enrichment) to identify single-stranded DNA or RNA oligonucleotides (aptamers) that bind with high affinity and specificity to a specific metal ion (e.g., Pb²⁺, Hg²⁺, UO₂²⁺, As³⁺, Cd²⁺). Unlike aptamers for proteins, metal ion aptamers often rely on the ion's unique coordination chemistry to induce a specific fold or structural switch in the oligonucleotide. Core Service Workflow (The Screening Process) A typical service provider would follow these steps: Design & Library Synthesis: Creation of a vast random-sequence oligonucleotide library (10¹⁴ - 10¹⁵ different sequences). Target Preparation: The target (e.g., Pb²⁺) is often presented in a specific buffer system that controls charge, pH, and the presence of competing ions to drive selection for the desired specificity. Selection Rounds (SELEX Cycle): Binding: Incubate the library with the target metal ion. Partition: Separate metal-bound sequences from unbound ones. This is the most critical and challenging step for small ions. Techniques include: Immobilization: Cheating the ion to a solid support (beads). Capture-SELEX: Using a complementary strand or an auxiliary molecule. Size-based separation: If binding induces a conformational change (e.g., dimerization). Amplification: PCR (for…

    2026-01-13
  • Toxin-Targeted Aptamer Screening Service

    What is an Aptamer? First, a quick definition: Aptamers are short, single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (like proteins, toxins, cells) with high affinity and specificity. They are often called "chemical antibodies" but offer advantages like easier synthesis, higher stability, and lower cost. What is Toxin-Targeted Aptamer Screening? This service involves the in vitro selection and development of custom aptamers designed to bind specifically to a toxic substance. The core technology is called SELEX (Systematic Evolution of Ligands by EXponential enrichment). The process screens vast random libraries (10^14 - 10^15 different sequences) against the toxin to isolate the few sequences that bind tightly and specifically. Key Steps in the Service Pipeline Project Consultation & Target Definition: Clarify the toxin (e.g., mycotoxins like Aflatoxin B1, marine toxins like Saxitoxin, bacterial toxins like Botulinum, environmental toxins like heavy metals). Define the desired application (Detection/Biosensing, Neutralization, Capture/Purification). Specify the sample matrix (food extract, blood serum, environmental water). Library Design & SELEX Strategy: Design of a naive single-stranded DNA or RNA library. Choosing the appropriate SELEX variant: Negative Selection/Counter-SELEX: To exclude sequences that bind to similar non-toxin molecules or the assay matrix (crucial for specificity). Capture-SELEX: For small toxins that can't be immobilized. Cell-SELEX: If the…

    2026-01-13
  • Aptamer Screening Service for Drug Discovery

    What is an Aptamer? Aptamers are single-stranded DNA or RNA oligonucleotides that fold into specific 3D shapes, enabling them to bind to target molecules (proteins, small molecules, cells, viruses) with high affinity and specificity, similar to antibodies. They are often called "chemical antibodies." Why Use Aptamer Screening Services in Drug Discovery? Efficiency: Outsourcing to experts with specialized platforms (SELEX) accelerates discovery. Cost-Effectiveness: Avoids capital investment in complex SELEX and NGS infrastructure. Expertise: Leverages specialized knowledge in oligonucleotide chemistry, bioinformatics, and target biology. Focus: Allows internal teams to concentrate on downstream therapeutic development. Core Components of an Aptamer Screening Service A full-service provider typically offers an end-to-end pipeline: 1. Project Design & Target Preparation Consultation: Defining the target (recombinant protein, cell surface marker, whole cell), desired affinity (nM-pM), and specificity (e.g., against homologs). Counter-SELEX Strategy: Planning to eliminate binders to non-desired epitopes or related targets to ensure high specificity. 2. In Vitro Selection (SELEX) The core technology is SELEX (Systematic Evolution of Ligands by EXponential enrichment). Advanced variants are used for complex targets: Protein-SELEX: For purified recombinant proteins. Cell-SELEX: For membrane proteins in their native conformation on live cells; identifies aptamers for diseased vs. healthy cells. Tissue-SELEX: For even more complex biological environments. Capture-SELEX: For small molecules that are difficult to immobilize. High-Throughput SELEX (HT-SELEX): Uses NGS early…

    2026-01-13
  • Aptamer Screening Services for Protein and Nucleic Acid Targets

    Core Technology: SELEX The foundation of all these services is the SELEX process, an in vitro method to select aptamers from a vast random library (typically 10^13 - 10^15 unique sequences). The library is incubated with the target, unbound sequences are washed away, and bound sequences are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA). This cycle is repeated 8-15 times to enrich for the tightest binders. Services for Protein Targets This is the most common application, as aptamers are often touted as "chemical antibodies." 1. Standard Protein SELEX: Target: Purified, recombinant proteins (e.g., cytokines, receptors, enzymes, viral capsids). Key Considerations: Protein Purity & Conformation: Critical for success. Services often require >90% purity and verification of native folding. Immobilization: The protein is usually immobilized on beads (e.g., streptavidin/biotin, Ni-NTA/His-tag) to facilitate partitioning. Some services offer solution-phase SELEX to avoid conformation changes. Counter-Selection: To ensure specificity, libraries are pre-incubated with related proteins or the immobilization matrix to subtract non-specific binders. 2. Specialized SELEX for Complex Proteins: Membrane Protein SELEX: For receptors and channels. Requires special handling (e.g., use of nanodiscs, detergent micelles, or whole cells overexpressing the target). Post-Translationally Modified Protein SELEX: For targets where phosphorylation, glycosylation, etc., are essential for function. 3. Cell-SELEX (for Cell-Surface…

    2026-01-12
  • Aptamer Screening Service for Protein Antibody Receptors

    What is an Aptamer Screening Service? It is a contract-based service where a specialized laboratory uses Systematic Evolution of Ligands by EXponential enrichment (SELEX) to discover single-stranded DNA or RNA molecules (aptamers) that bind with high affinity and specificity to your target molecule (e.g., a protein, an antibody's constant region, or a cell-surface receptor). Core Service Components A full-service provider typically offers an end-to-end pipeline: 1. Project Design & Target Preparation Consultation: Defining the goal (e.g., detection, inhibition, delivery). Target Characterization: Ensuring the target (purified protein, antibody, receptor-expressing cells) is properly formatted and validated. Negative Selection/Counter-SELEX: Designing the screening to avoid binders to similar, non-target structures (e.g., the Fc region of a different antibody isotype, a common cell surface protein). 2. Library & Selection (The Core SELEX Process) Library Design: Using a diverse random oligonucleotide library (typically 10^14 - 10^15 unique sequences). Selection Method: The choice of method is critical and depends on the target: Protein SELEX: For purified, soluble targets immobilized on beads or in solution. Cell-SELEX: For membrane receptors in their native conformation on live cells. Excellent for discovering aptamers to unknown receptor complexes. Capture-SELEX/Toggle-SELEX: For difficult-to-immobilize targets or to increase stringency. In Vivo SELEX: For discovering aptamers that home to specific tissues in vivo. Iterative Rounds: Typically 8-15 rounds of…

    2026-01-12
  • Aptamer Screening Service-Targeting Protein Cytokines

    What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that folds into a specific 3D structure, allowing it to bind to a target molecule (like a cytokine) with high affinity and specificity, akin to a monoclonal antibody. Why Target Cytokines with Aptamers? Cytokines are key signaling proteins in immune and inflammatory responses. Dysregulation is implicated in diseases like: Autoimmune disorders: Rheumatoid arthritis, psoriasis, inflammatory bowel disease. Cancer: Tumor microenvironment signaling. Cytokine Storms: Severe COVID-19, sepsis. Neurological diseases. Aptamers offer advantages over traditional antibody-based therapies: High Specificity: Can distinguish between closely related cytokine isoforms or conformational states. Controlled Synthesis: Chemically produced, no batch-to-batch variation. Modifiability: Easily conjugated with drugs, fluorophores, or nanoparticles. Low Immunogenicity: Less likely to cause an immune response. Stability: Generally more stable than proteins. The Aptamer Screening Service Workflow (SELEX) A professional service will manage the entire SELEX (Systematic Evolution of Ligands by EXponential Enrichment) process. Here’s a typical pipeline: Phase 1: Project Design & Target Preparation Consultation: Define the goal—neutralization, detection, or delivery. Target Selection: Which cytokine? (e.g., TNF-α, IL-6, IL-1β, IFN-γ). Requires a high-purity, bioactive protein. Services often help with recombinant expression/purification if needed. Library Design: A vast random-sequence oligonucleotide library (10^14-10^15 unique sequences) is the starting point. Libraries can be DNA, RNA, or contain modified…

    2026-01-12
  • Aptamer Screening Service-Protein-Specific Selection

    What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that binds to a specific target molecule (like a protein) with high affinity and specificity. They are often called "chemical antibodies" but offer advantages like smaller size, chemical stability, and in-vitro generation. The Core Service: SELEX (Systematic Evolution of Ligands by EXponential Enrichment) The standard method for aptamer screening is SELEX. A specialized service will manage this entire iterative, high-complexity process for you. General SELEX Workflow: Target Preparation & Immobilization: Your service provider will prepare your purified protein. It is often immobilized on a solid support (beads, column, plate) to separate bound from unbound sequences. Incubation with Library: A vast, random synthetic oligonucleotide library (10^13 - 10^15 unique sequences) is incubated with the target. Partitioning: Weak or non-binding sequences are washed away. Tightly bound aptamers are retained. Elution & Amplification: The bound sequences are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA). Stringency & Counter-SELEX: Subsequent rounds introduce increased washing stringency and incubation with non-target molecules (e.g., similar proteins, immobilization matrix) to filter out non-specific binders. This is crucial for specificity. Cloning & Sequencing: After 8-15 rounds, the enriched pool is cloned and sequenced to identify individual candidate aptamers. Characterization &…

    2026-01-12